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Abstract
Background: Class II Major Histocompatibility Complex (MHC) molecules have an open-ended
binding groove which can accommodate peptides of varying lengths. Several studies have
demonstrated that peptide flanking residues (PFRs) which lie outside the core binding groove can
influence peptide binding and T cell recognition. By using data from the AntiJen database we were
able to characterise systematically the influence of PFRs on peptide affinity for MHC class II
molecules.
Results: By analysing 1279 peptide elongation events covering 19 distinct HLA alleles it was
observed that, in general, peptide elongation resulted in increased MHC class II molecule affinity.
It was also possible to determine an optimal peptide length for MHC class II affinity of
approximately 18–20 amino acids; elongation of peptides beyond this length resulted in a null or
negative effect on affinity.
Conclusion: The observed relationship between peptide length and MHC class II affinity has
significant implications for the design of vaccines and the study of the epitopic basis of
immunological disease.
Background
Classical major histocompatibility complex (MHC) mol-
ecules are divided into two groups: class I and class II [1].
Each contains large numbers of alleles, all of which bind
antigen for cell surface presentation to T cells. MHC class
I molecules comprise a single polymorphic chain coupled
to a single conserved protein: β2 microglobulin. In con-
trast, MHC class II molecules comprise two polymorphic
subunits: an α and a β chain. A notable difference between
the classes is the open-ended peptide-binding groove of
MHC class II molecules compared to the closed binding
site of MHC class I. This feature, which has been observed
in many X-ray crystallographic structures, has been used
to explain the observed differences in peptide length
accommodated by the two classes [2-4]. Class I molecules
typically accommodate peptides of eight to ten residues,
although instances of longer peptide binding have now
been reported [5].
In contrast, MHC class II molecules can accommodate
much longer peptides. Stern et al. investigated an influ-
enza-derived peptide complexed with HLA-DR1; they saw
the peptide bound in an extended conformation with five
binding pockets, which engaged peptide side chains,
while the flanking regions extended out of the groove [3].
Since MHC class II molecules have an open-ended bind-
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bound peptides. The length of peptides occupying the
groove can vary considerably as a consequence of semi-
stochastic proteolytic degradation [6].
Several studies have shown the influence of residues out-
side the main nonameric core on binding and subsequent
T cell recognition. Residues outside the nonameric bind-
ing region but within an extended binding groove have
been called peptide-flanking residues (PFRs) [7]. The
importance of PFRs for T cell recognition has also been
investigated. It is widely accepted that these flanking
regions can contribute to T cell mediated pMHC recogni-
tion [8]. Arnold and colleagues showed that certain T cell
responses were completely dependent on residues at pep-
tide positions P-1 and P11. Similar findings were reported
by Stepniak et al for immunostimulatory HLA-DQ2 bind-
ing peptides derived from gliadin and glutenin proteins
[9]. The findings of both authors can be partly explained
by the results of X-ray crystallographic studies of peptide-
MHC class II-TCR trimolecular complexes [10,11]. These
reports indicate that the CDR3 regions of the TCR α and β
chains tend to locate over the p5 residue in the binding
groove allowing the TCR to interact with the PFRs. It has
also been shown that the properties of residues in the
PFRs can influence T cell recognition, with residues capa-
ble of forming salt-bridges or hydrogen bonding with the
TCR being most favoured [8].
Much circumstantial if anecdotal evidence suggests that
PFRs contribute strongly to peptide-MHC stability. They
can provide an increased measurable affinity of peptide
for the MHC binding groove, in particular the residue at
position P-1 [12]. Nelson et al. reported that the effect of
increased stability was greater for a peptide length increase
of six amino acids compared to four. They also found the
effect to differ depending on which terminus was elon-
gated. Moreover, a previous study by Srinivasan et al
showed increased affinity resulting from the peptide elon-
gation of a single peptide [13]. How such peptide elonga-
tions might increase affinity remains unclear. Although it
is theoretically possible PFRs interact with the MHC mol-
ecules outside the groove, this has yet to be shown exper-
imentally, nor has it been seen in X-ray crystallographic
structures.
We have sought to elucidate this phenomenon further, by
examining the relationship between peptide length and
MHC class II affinity. We devised custom algorithms and
applied them to data available in the AntiJen database
[14] to firstly ascertain whether peptide length can impact
on affinity of a peptide for an MHC class II molecule. This
was assessed by searching the database for instances of
peptide elongation and determining the reported effect on
MHC class II affinity. Following this, we examined
whether there was a demonstrable limit to the effect of
peptide length on MHC class II affinity and subsequently
determined whether any effects on affinity were peptide
terminus specific. Our analysis indicated the positive
impact of peptide length on affinity. We also identified an
optimal length for peptide-MHC class II binding and
demonstrated that the effects on peptide affinity are termi-
nus independent.
Results
Most peptide elongation events result in enhanced affinity
The relationship between peptide length and MHC class II
affinity was examined using a dataset of peptide elonga-
tion events. This dataset comprised instances of elonga-
tion and their measured impact on MHC class II affinity
for several distinct peptides and MHC alleles under nor-
malised experimental conditions. Analysis of MHC class II
binding data from the AntiJen database using bespoke
algorithms generated 1279 elongation events. The dataset
covered 19 distinct HLA alleles from the DR, DP and DQ
loci. Most alleles were HLA-DR (Table 1). Within the data-
set, DRB1*0401 was the most prominent: 25.76 percent
of the characterised epitopes bound to this allele. A histo-
gram showing the effects of peptide elongation on affinity
is shown in Figure 1. Most affinity differences observed
were positive. Visual examination of the affinity histo-
gram shows an extreme value distribution with an elon-
gated right tail, indicating a clear trend towards increased
affinity in most observed binding events. However, fur-
ther analysis was required to ascertain the magnitude of
the effect when controlling for length of elongation and
peptide length.
Peptide elongation below an optimal length results in 
enhanced affinity
The relationship between final peptide length and affinity
was stratified by length of increase. A regression line was
Table 1: Chi Square Table for the observed elongation events.
Amino Both Carboxy All
Decreased (Observed) 120 80 92 292
Decreased (Expected) 120.3 81.5 90.2 292
Increased (Observed) 407 277 303 987
Increased (Expected) 406.7 275.5 304.8 987
All 527 357 395 1279
A standard chi-square table examining bias in the observed affinity 
increase/decrease towards a particular peptide terminus. Rows show 
effect (Affinity Increase or Decrease), whereas, the columns show the 
terminus at which the elongation was observed.Page 2 of 7
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scarcity, only increases of one to five residues were ana-
lysed. Regression analysis relating the size of peptide elon-
gations to the final length of peptides and the observed
affinity indicates that a larger increase in peptide length
leads to a greater gain in affinity. However, from Figure 2,
it is clear that a point exists (~18–20 residues in length),
beyond which there is no advantage to be gained from
peptide elongation. From Figure 2, it is also clear that the
positive effect on affinity due to peptide elongation less-
ens as peptide length increases. Examination of Figure 2
reveals that, if one were to measure the affinity of a nona-
meric peptide for a given MHC molecule, then serially
elongating the peptide by a single residue and re-measur-
ing the affinity, the first elongation may (on average) add
2 units to the affinity. Adding a single residue to the pep-
tide to make it 16 residues long would add only 0.8 units
to the affinity. By the time the peptide had reached 18 res-
idues in length further elongation would decrease the
affinity for the MHC molecule.
The observed effect is terminus independent
A chi-square analysis was performed to determine if the
observed effect of increased peptide-MHC class II affinity
was terminus specific. Elongation events were classified by
whether they resulted in an increase or a decrease in bind-
ing affinity. Events were also classified based on whether
they occurred at the amino or carboxy terminus or both.
A summary of the observed incidence of terminus addi-
tions and positive and negative effects on affinity are
shown in Table 2. A preponderance of favourable interac-
tions at a particular terminus might suggest that the pep-
tide elongations at that terminus facilitated favourable
interactions either inside or outside of the binding groove.
The chi-square analysis indicated no significant difference
between changes recorded at either termini (p = 0.959),
indicating an absence of statistically significant bias. This
may point to a more general, terminus independent effect
on affinity.
Discussion
While MHC class II molecules and their ligands are well
characterised, the impact of peptide length on MHC affin-
Histogram of the affinity differences observed in the peptide elongation datasetFigure 1
Histogram of the affinity differences observed in the peptide elongation dataset. Observed effects on affinity for 
each peptide elongation are plotted based on the frequency of occurrence. It is possible to visualise the most common affinity 
difference (+0.5), the most extreme affinity difference (+9.0) and the ratio of positive to negative effects. For ease of interpre-
tation the bar representing the number of instances where no effect on affinity was observed is highlighted.Page 3 of 7
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vations have purported to show that peptide length may
influence affinity we have for the first time systematically
quantified this relationship using in silico analysis. Using
novel computational analyses, we exploit the wealth of
manually-curated quantitative binding data available
within the AntiJen database [14].
When attempting to derive a relationship between
sequence length and observed MHC affinity, one is lim-
ited by several factors. One such factor is the presence of
different binding determinants in most sequences that
could significantly bias any simple length-affinity correla-
tion. Thus, if one examines the affinity of two sequences
of different length and low sequence similarity, one can-
not ascertain if an altered affinity is due to differences in
the binding determinant or to changes in sequence length.
To isolate such a relationship, one must normalise all fac-
tors (such as MHC allele, experimental conditions, and
peptide sequence) except for sequence length before ana-
lysing the affect on affinity. To that end, we identified
examples of affinity measurements, for a single sequence
and an elongated equivalent, which were performed
under the same experimental conditions. The benefits of
this approach were twofold. Firstly, inter-laboratory varia-
tion in affinity measurements would be excluded. Sec-
ondly, bias from variations in the binding determinant
would also be reduced if not eliminated, thus removing
bias from intra- but not inter-sequence comparisons. Bias
from inter-sequence comparisons is unavoidable. We
optimised for the required task in order to avoid repre-
senting bias as effect.
The data presented in Figure 2 allowed us to examine the
limits of the effect with respect to final peptide length. By
examining the log fold-change in affinity for MHC class II
as the length of the peptide increases it can clearly be seen
that the impact on affinity lessens. The regression plot also
shows that at approximately 19 amino acids the effect of
peptide elongation on affinity becomes zero. Elongating
Regression plot of classes of peptide length additionsFigure 2
Regression plot of classes of peptide length additions. Five regression lines relating observed differences in affinity to 
final peptide length for each magnitude of peptide elongation. The content of this figure shows two important points relating 
sequence length and MHC class II affinity. Firstly, when correcting for final peptide length a greater length addition will generate 
a greater increase in affinity e.g. for peptides with a final length of 14 amino acids increasing the length by four residues has a 
much greater effect than a single residue increase. Secondly, from the included data it is possible to observe a length of 
between 18 and 20 amino acids, beyond which, increasing the length of the peptide has a null or negative effect.Page 4 of 7
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cases – result in a diminished affinity. This seems logical:
if no such ceiling existed for the positive effect of peptide
length then sequence length alone would be the key deter-
minant of peptide-MHC affinity. This discovery is also
strengthened by the findings of Lippolis et al. who eluted
and sequenced peptides from HLA-DR*0401 and found
that the most abundant species within a family of nested
peptides were between 14 and 21 residues in length [15].
Our findings do not however suggest that a single optimal
length would exist for all peptides for all MHC class II alle-
les, and indeed the relative heterogeneity of peptides
binding to MHC class II molecules is well reported [15-
17]. However, this approximation to an optimal length is
consistent for a large number of peptide sequences and a
large number of MHC class II alleles.
Many explanations for this length ceiling present them-
selves. It may be that as peptides become very long they
are no longer able to form favourable interactions with
the MHC or TCR. Alternatively, when MHC class II bind-
ing peptides attain a certain length they may form second-
ary or tertiary structures outside the binding site that are
less compatible with MHC class II binding. An exception
to this rule may be the 33-amino acid peptide initially
described by Shan et al [18]. It binds to HLA-DQ2 and
stimulates disease associated T cells. Despite its unusual
length, this peptide retains its MHC class II binding abili-
ties as its proline rich nature helps it to form a type II poly-
proline helix. This is the conformation normally seen in
MHC class II binding grooves [3].
Our results clearly imply a general correlation between
increasing MHC binding affinity and increasing peptide
length. It is not peculiar to a restricted subset of peptides.
Sercarz and Maverakis posited that longer peptides have a
greater binding affinity for MHC class II [19]; this asser-
tion was based on observations from a few articles, e.g. the
study by Srinivasan et al [13]. However, to the best of our
knowledge, ours is the first study to test this hypothesis
systematically for several MHC class II alleles. The results
of our study are compelling: across 1279 identified pep-
tide elongation events for peptides binding to 19 distinc-
tive MHC class II alleles, affinity predominately increased.
It is important to note, however, that the examined pep-
tides are more representative of the HLA-DR species than
either HLA-DP or HLA-DQ, and this may result from an
apparent publication bias in favour of HLA-DR which will
be reflected in the AntiJen database.
Our findings have clear implications for experimental
immunology and vaccinology, as well as computational
immunology; and these implications are many. Increased
affinity in vivo may result in increased reactivity to recently
degraded peptides. Presumably, recently degraded pep-
tides may be less completely digested and – as a result of
increased length – have an increased affinity for MHC
class II relative to shorter more fully degraded peptides.
Such an effect would, in theory, increase the likelihood of
T cells recognising more recently endocytosed peptides
rather than a background of self-peptides. Additionally,
the ability of exopeptidases to digest termini of peptides
within the MHC class II binding cleft [6] may effectively
reduce their MHC class II affinity. Thus, peptides suscepti-
Table 2: Composition of the dataset of elongation events.
Allele Count Percent
DPB1*0401 38 2.97
DPB1*0402 38 2.97
DQA1*0301/DQB1*0301 64 5
DQA1*0501/DQB1*0201 114 8.91
DRB1*0101 124 9.7
DRB1*0301 1 0.08
DRB1*0401 77 6.02
DRB1*0404 2 0.16
DRB1*0405 3 0.23
DRB1*0802 3 0.23
DRB1*0803 2 0.16
DRB1*0901 3 0.23
DRB1*1101 3 0.23
DRB1*1201 3 0.23
DRB1*1302 3 0.23
DRB1*1501 682 53.32
DRB3*0101 24 1.88
DRB4*0101 1 0.08
DRB5*0101 94 7.35
Total N = 1279 100
The dataset of peptide elongation events contained a total of 1279 
elongation events covering 19 distinct alleles. The representative 
numbers for each allele are preresented as raw counts and 
percentages.Page 5 of 7
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immunogenic in vitro. The field of subunit vaccine design
may be able to augment vaccine efficacy by increasing
peptide length or eliminating potential proteolytic cleav-
age sites, which may result in an inability of normal pro-
teolytic enzymes to digest peptides to shorter equivalents
with reduced immunogenicity.
Conclusion
Using an in silico approach we were able to define a rela-
tionship between peptide length and MHC class II affin-
ity. The results of this study demonstrate that, within
limits, elongation of a peptide is likely to result in a
greater affinity for MHC class II molecules. It was also pos-
sible to show that the optimal length for peptide-MHC
affinity was approximately 18–20 amino acids. Addition-
ally, it was also possible to demonstrate that the effects are
consistent regardless of which terminus was elongated.
Given the well-characterised importance of peptide-MHC
interaction to the cellular immune response, it is likely
that the findings of this study will prove of significance in
vaccine design and the epitopic basis of immunological
disease.
Methods
Dataset formation
Data for the study were obtained by querying the AntiJen
database [14] for all sequences known to bind human
MHC class II molecules. These data were imported into a
spreadsheet and then further filtered to exclude those data
for which no radiometrically determined IC50 value were
present. IC50 values were then transformed to their -
lnIC50. This dataset was then output to a text file contain-
ing epitope sequence, -lnIC50 value, pubmed ID of the
source article, experimental conditions and the MHC
binding allele. This database formed the source data for
interrogation using a bespoke algorithm.
Data query algorithm
To analyse the data it was decided to search for peptides
for which elongation events were recorded. Different
experimental conditions can give rise to variance in
reported IC50 values for a single peptide binding to a sin-
gle MHC allele. To circumvent any bias which may be
introduced by comparing such peptides, it was decided to
look for peptide elongation events which were performed
under the same experimental conditions and published in
a single article. In order to perform this search an algo-
rithm was implemented in Python to search within a sin-
gle publication for the affinity determination of a peptide
and a longer counterpart. The algorithm (Figure 3) itera-
tively considers each peptide in order of increasing length
and then searches within the publication for longer coun-
terparts. Thus, the algorithm begins with the shortest pep-
tides and looks for longer peptides, which represent
elongated versions of the original peptide, measured
under the same experimental conditions and published in
the same paper. For both peptides the algorithm com-
putes the difference in reported binding affinity and stores
it in an output file with the original peptide sequence, the
elongated peptide sequence and additional data such as
peptide length and the Pubmed ID number of the source
publication. The output file was formatted for easy entry
into a statistical analysis package.
Statistical analysis of elongation data
All statistical analyses were performed using the Minitab®
software package (Minitab Inc) for statistical analysis. Dis-
crete datasets were isolated for particular analyses such as
the chi-square analysis using Microsoft Excel®.
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